Immune thrombocytopenia

Haematopoiesis

Biology

Thrombopoietin

Clinical trial

Stem cell

Receptor

Eltrombopag

Romiplostim

Immunology

Genetics

Tyrosine kinase

Internal medicine

Medicine

Antibody

Platelet

Blood

Fostamatinib is a spleen tyrosine kinase inhibitor recently approved for the treatment of chronic immune thrombocytopenia (ITP) in patients without adequate response to at least 1 prior line of therapy. This article reviews fostmatinib's mechanism of action and its clinical safety and efficacy in 2 industry-sponsored multicenter phase 3 randomized controlled trials in North America, Australia, and Europe (FIT1 and FIT2). Cost comparisons are discussed as well as the role of fostamatinib in relation to other options for chronic ITP.

Fostamatinib for the treatment of chronic immune thrombocytopenia